Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing
challenge in terms of prevention and treatment. Despite its high prevalence, only a small …

Non-alcoholic fatty liver disease (NAFLD) has a prevalence of 25–30% in unselected
populations and has become the main reason for referrals to hepatology services. From the …

Background & Aims Nonalcoholic steatohepatitis (NASH) is a leading cause of liver
transplantation, and many trials are underway to evaluate potential therapies. The farnesoid …

Chronic hepatitis B virus (HBV) infection is a major cause of liver morbidity and mortality
worldwide. While a proportion of the 250 million individuals chronically infected with HBV …

Abstract Background & Aims Hyperferritinemia, with or without increased hepatic iron,
represents a common finding in non‐alcoholic fatty liver disease (NAFLD). However, it is …

Nonalcoholic fatty liver disease (NAFLD), tightly linked to the metabolic syndrome (MS), has
emerged as a leading cause of chronic liver disease worldwide. Since it is potentially …

Background/aims Non‐invasive fibrosis tests (NITs) can be used to triage non‐alcoholic fatty
liver disease (NAFLD) patients at risk of advanced fibrosis (AF). We modelled and …

The development and validation of non-invasive fibrosis tests (NITs) has changed clinical
practice in Hepatology over the last 15 years. Metabolic associated steatotic liver disease …

Transient elastography by FibroScan®(Echosens, Paris, France) is a non-invasive method
that can provide a reliable measurement of liver fibrosis through the evaluation of liver …

Methods The diagnostic performance of each noninvasive test according to previously
identified cutoff points indicating low and high risk for advanced fibrosis was determined in …